Avicanna Inc. (AVCNF)
OTCMKTS
· Delayed Price · Currency is USD
0.1845
-0.0055 (-2.89%)
Jun 23, 2025, 2:55 PM EDT
Avicanna Revenue
Avicanna had revenue of 6.32M CAD in the quarter ending March 31, 2025, a decrease of -1.88%. This brings the company's revenue in the last twelve months to 25.34M, up 14.82% year-over-year. In the year 2024, Avicanna had annual revenue of 25.46M with 51.62% growth.
Revenue (ttm)
25.34M CAD
Revenue Growth
+14.82%
P/S Ratio
1.22
Revenue / Employee
291.24K CAD
Employees
87
Market Cap
21.55M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Elite Pharmaceuticals | 70.00M |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
American Oncology Network | 1.76B |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Avicanna News
- 4 weeks ago - Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain - GlobeNewsWire
- 5 weeks ago - Avicanna Reports Q1 2025 Results and First Profitable Quarter - GlobeNewsWire
- 2 months ago - Avicanna Inc. (AVCNF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Avicanna Announces Revocation of Management Cease Trade Order - GlobeNewsWire
- 2 months ago - Avicanna Reports Full Year 2024 Audited Financial Statement - GlobeNewsWire
- 2 months ago - Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update - GlobeNewsWire
- 2 months ago - Avicanna Announces its 5th Medical Symposium on Cannabinoid-based Medicine - GlobeNewsWire
- 3 months ago - Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order - GlobeNewsWire